曲妥珠单抗、吉西他滨和紫杉醇联合治疗老年女性乳腺癌人表皮生长因子受体2阳性伴肺转移患者的临床研究  

A clinical study of combination treatment of trastuzumab,gemcitabine and paclitaxel in elderly patients with HER2-positive breast cancer and lung metastasis

作　　者：石晶晶[1] 王宗宝 李长江[1] 宋晓霞[1] Shi Jingjing;Wang Zongbao;Li Changjiang;Song Xiaoxia(First Aid Centre,Central Hospital of Qingdao City(Second Clinical Medical College of Qingdao University),Qingdao,Shandong,266042,P.R.China;Department of Emergency Surgery,Traditional Chinese Medicine Hospital of Qingdao City,Qingdao,Shandong,266033,P.R.China)

机构地区：[1]青岛市中心医院(青岛大学第二临床医学院)急救中心,山东青岛266042 [2]青岛市中医院急诊外科,山东青岛266033

出　　处：《老年医学与保健》2020年第5期767-770,共4页Geriatrics & Health Care

摘　　要：目的分析曲妥珠单抗、吉西他滨和紫杉醇联合治疗老年女性乳腺癌人表皮生长因子受体2(HER2)阳性伴肺转移患者的效果,为治疗该病症提供方法。方法选择2009年1月-2019年12月在青岛市中心医院治疗的200例老年女性乳腺癌HER2阳性伴肺转移的患者,随机分为观察组和对照组,每组100例。对照组采取曲妥珠单抗和吉西他滨联合治疗,观察组采取曲妥珠单抗、吉西他滨和紫杉醇联合治疗。评估并比较2组治疗前后血清肿瘤标志物和免疫功能指标变化,以及治疗效果和不良反应。结果治疗后,观察组癌胚抗原(CEA)、糖蛋白125(CA125)、糖蛋白153(CA153)和多肽特异性抗原(TPS)水平均明显低于对照组(P<0.05),观察组CD3^+、CD4^+、CD4^+/CD8^+以及NK水平均高于对照组,CD8^+低于对照组,差异均有统计学意义(P<0.05)。观察组临床治疗客观缓解率和临床收益率均明显高于对照组(P<0.05),观察组不良反应发生率明显高于对照组(P<0.05)。结论老年乳腺癌HER2阳性伴肺转移患者使用曲妥珠单抗、吉西他滨和紫杉醇联合治疗,有利于促进血清肿瘤标志物水平的下降,改善免疫功能,疗效良好,具有一定的应用价值。Objective To analyze the effect of combination treatment of trastuzumab,gemcitabine and paclitaxel in elderly patients with human epidermal growth factor receptor 2(HER2)positive breast cancer and lung metastases.Methods From January 2009 to December 2019,200 elderly female breast cancer patients with HER2 positive and lung metastasis treated in central hospital of Qingdao city were randomly divided into observation group and control group,with 100 cases in each group.The control group was treated with trastuzumab and gemcitabine,while the observation group was treated with trastuzumab,gemcitabine and paclitaxel.The changes of serum tumor markers and immune function indexes,therapeutic effects and adverse reactions were evaluated and compared between the two groups before and after treatment.Results After treatment,the levels of carcinoembryonic antigen(CEA),glycoprotein 125(CA125),glycoprotein 153(CA153),and peptide-specific antigen(TPS)of the observation group were significantly lower than those of the control group(P<0.05),the levels of CD3^+,CD4^+,CD4^+/CD8^+and NK of the observation group were higher than those of the control group,and the level of CD8^+of the observation group was lower than that of the control group(P<0.05).The objective remission rate and clinical benefit rate of clinical treatment in the observation group was higher than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was higher than that in the control group(P<0.05).Conclusion The combination treatment of trastuzumab,gemcitabine and paclitaxel in elderly patients with HER2 positive breast cancer and lung metastasis can promote the decline of serum tumor markers,improve immune function,and have a certain application value.

关 键 词：老年 乳腺癌 人表皮生长因子受体2 曲妥珠单抗 吉西他滨 紫杉醇 

分 类 号：R737.9[医药卫生—肿瘤]